Copyright Reports & Markets. All rights reserved.

Global Benign Prostatic Hyperplasia Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Benign Prostatic Hyperplasia Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Drug Class
      • 1.4.3 Minimally Invasive Surgeries
      • 1.4.4 Laser Therapy
      • 1.4.5 Others
    • 1.5 Market by Application
      • 1.5.1 Global Benign Prostatic Hyperplasia Treatment Market Share by Application (2019-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Ambulatory Surgical Centers
      • 1.5.4 Specialty Clinics
      • 1.5.5 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Benign Prostatic Hyperplasia Treatment Market Size
    • 2.2 Benign Prostatic Hyperplasia Treatment Growth Trends by Regions
      • 2.2.1 Benign Prostatic Hyperplasia Treatment Market Size by Regions (2019-2025)
      • 2.2.2 Benign Prostatic Hyperplasia Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Benign Prostatic Hyperplasia Treatment Market Size by by Players
      • 3.1.1 Global Benign Prostatic Hyperplasia Treatment Revenue by by Players (2014-2019)
      • 3.1.2 Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Benign Prostatic Hyperplasia Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Benign Prostatic Hyperplasia Treatment Key Players Head office and Area Served
    • 3.3 Key Players Benign Prostatic Hyperplasia Treatment Product/Solution/Service
    • 3.4 Date of Enter into Benign Prostatic Hyperplasia Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Benign Prostatic Hyperplasia Treatment Market Size by Type (2014-2019)
    • 4.2 Global Benign Prostatic Hyperplasia Treatment Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Benign Prostatic Hyperplasia Treatment Market Size (2014-2019)
    • 5.2 Benign Prostatic Hyperplasia Treatment Key Players in North America
    • 5.3 North America Benign Prostatic Hyperplasia Treatment Market Size by Type
    • 5.4 North America Benign Prostatic Hyperplasia Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Benign Prostatic Hyperplasia Treatment Market Size (2014-2019)
    • 6.2 Benign Prostatic Hyperplasia Treatment Key Players in Europe
    • 6.3 Europe Benign Prostatic Hyperplasia Treatment Market Size by Type
    • 6.4 Europe Benign Prostatic Hyperplasia Treatment Market Size by Application

    7 China

    • 7.1 China Benign Prostatic Hyperplasia Treatment Market Size (2014-2019)
    • 7.2 Benign Prostatic Hyperplasia Treatment Key Players in China
    • 7.3 China Benign Prostatic Hyperplasia Treatment Market Size by Type
    • 7.4 China Benign Prostatic Hyperplasia Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Benign Prostatic Hyperplasia Treatment Market Size (2014-2019)
    • 8.2 Benign Prostatic Hyperplasia Treatment Key Players in Japan
    • 8.3 Japan Benign Prostatic Hyperplasia Treatment Market Size by Type
    • 8.4 Japan Benign Prostatic Hyperplasia Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Benign Prostatic Hyperplasia Treatment Market Size (2014-2019)
    • 9.2 Benign Prostatic Hyperplasia Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Benign Prostatic Hyperplasia Treatment Market Size by Type
    • 9.4 Southeast Asia Benign Prostatic Hyperplasia Treatment Market Size by Application

    10 India

    • 10.1 India Benign Prostatic Hyperplasia Treatment Market Size (2014-2019)
    • 10.2 Benign Prostatic Hyperplasia Treatment Key Players in India
    • 10.3 India Benign Prostatic Hyperplasia Treatment Market Size by Type
    • 10.4 India Benign Prostatic Hyperplasia Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Benign Prostatic Hyperplasia Treatment Market Size (2014-2019)
    • 11.2 Benign Prostatic Hyperplasia Treatment Key Players in Central & South America
    • 11.3 Central & South America Benign Prostatic Hyperplasia Treatment Market Size by Type
    • 11.4 Central & South America Benign Prostatic Hyperplasia Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 Abbott
      • 12.1.1 Abbott Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Benign Prostatic Hyperplasia Treatment Introduction
      • 12.1.4 Abbott Revenue in Benign Prostatic Hyperplasia Treatment Business (2014-2019))
      • 12.1.5 Abbott Recent Development
    • 12.2 Allergan plc
      • 12.2.1 Allergan plc Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Benign Prostatic Hyperplasia Treatment Introduction
      • 12.2.4 Allergan plc Revenue in Benign Prostatic Hyperplasia Treatment Business (2014-2019)
      • 12.2.5 Allergan plc Recent Development
    • 12.3 Astellas Pharma
      • 12.3.1 Astellas Pharma Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Benign Prostatic Hyperplasia Treatment Introduction
      • 12.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Treatment Business (2014-2019)
      • 12.3.5 Astellas Pharma Recent Development
    • 12.4 Asahi Kasei Corporation
      • 12.4.1 Asahi Kasei Corporation Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Benign Prostatic Hyperplasia Treatment Introduction
      • 12.4.4 Asahi Kasei Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2014-2019)
      • 12.4.5 Asahi Kasei Corporation Recent Development
    • 12.5 Boehringer Ingelheim GmbH
      • 12.5.1 Boehringer Ingelheim GmbH Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Benign Prostatic Hyperplasia Treatment Introduction
      • 12.5.4 Boehringer Ingelheim GmbH Revenue in Benign Prostatic Hyperplasia Treatment Business (2014-2019)
      • 12.5.5 Boehringer Ingelheim GmbH Recent Development
    • 12.6 GlaxoSmithKline
      • 12.6.1 GlaxoSmithKline Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Benign Prostatic Hyperplasia Treatment Introduction
      • 12.6.4 GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia Treatment Business (2014-2019)
      • 12.6.5 GlaxoSmithKline Recent Development
    • 12.7 Pfizer
      • 12.7.1 Pfizer Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Benign Prostatic Hyperplasia Treatment Introduction
      • 12.7.4 Pfizer Revenue in Benign Prostatic Hyperplasia Treatment Business (2014-2019)
      • 12.7.5 Pfizer Recent Development
    • 12.8 Sanofi
      • 12.8.1 Sanofi Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Benign Prostatic Hyperplasia Treatment Introduction
      • 12.8.4 Sanofi Revenue in Benign Prostatic Hyperplasia Treatment Business (2014-2019)
      • 12.8.5 Sanofi Recent Development
    • 12.9 Teva Pharmaceutical Industries
      • 12.9.1 Teva Pharmaceutical Industries Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Benign Prostatic Hyperplasia Treatment Introduction
      • 12.9.4 Teva Pharmaceutical Industries Revenue in Benign Prostatic Hyperplasia Treatment Business (2014-2019)
      • 12.9.5 Teva Pharmaceutical Industries Recent Development
    • 12.10 Merck
      • 12.10.1 Merck Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Benign Prostatic Hyperplasia Treatment Introduction
      • 12.10.4 Merck Revenue in Benign Prostatic Hyperplasia Treatment Business (2014-2019)
      • 12.10.5 Merck Recent Development
    • 12.11 Boston Scientific Corporation
    • 12.12 Teleflex Incorporated
    • 12.13 Endo International
    • 12.14 Urologix
    • 12.15 LISA Laser
    • 12.16 Olympus

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global Benign Prostatic Hyperplasia Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Benign Prostatic Hyperplasia Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Benign Prostatic Hyperplasia Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Abbott
      Allergan plc
      Astellas Pharma
      Asahi Kasei Corporation
      Boehringer Ingelheim GmbH
      GlaxoSmithKline
      Pfizer
      Sanofi
      Teva Pharmaceutical Industries
      Merck
      Boston Scientific Corporation
      Teleflex Incorporated
      Endo International
      Urologix
      LISA Laser
      Olympus

      Market segment by Type, the product can be split into
      Drug Class
      Minimally Invasive Surgeries
      Laser Therapy
      Others

      Market segment by Application, split into
      Hospitals
      Ambulatory Surgical Centers
      Specialty Clinics
      Others

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Benign Prostatic Hyperplasia Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Benign Prostatic Hyperplasia Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Benign Prostatic Hyperplasia Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now